Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
In SUSTAIN-7, a study comparing semaglutide to dulaglutide in patients with inadequately controlled T2DM, a greater reduction in body weight was observed with 0.5 mg semaglutide (4.6 kg, standard error [SE] 0.28) compared with 0.75 mg dulaglutide (2.3 kg, SE 0.27) (estimated treatment difference [ETD] 2.26 kg, 95% CI 3.02 to 1.51
Insulin enhances growth hormone induction of the MEK/ERK signaling pathway
While long-term data on stopping and switching are still emerging, oral options provide an evidence-backed alternative for people who prefer not to use injectables
Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors
They provide a roadmap so you launch faster and smarter
US$ 22.52
US$ 24.05
US$ 28.27
US$ 28.97
US$ 25.83
US$ 28.96
